Jiang Zhi Granule protects immunological barrier of intestinal mucosa in rats with non-alcoholic steatohepatitis

Yu, Xiao; Zhang, Haiyan; Pan, Jielu; Zou, Lu; Tang, Ling; Miao, Hongyu; Zheng, Peiyong; Xing, Lian-Jun

doi:10.1080/13880209.2021.1979594

Cited by 5 publications

(5 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For instance, Polygoni Multiflori Radix reduced steatosis in zebrafish and human liver cells via lipid metabolism [59,60]. Jiang-Zhi granules were proven to inhibit NAFLD mainly by ameliorating inflammation [61]. Phloroglucinol has been shown to have anti-NAFLD activity by strengthening the antioxidant barrier and reducing oxidative stress in liver cells [62].…”

Section: Discussionmentioning

confidence: 99%

Lian-Mei-Yin formula alleviates diet-induced hepatic steatosis by suppressing Yap1/FOXM1 pathway-dependent lipid synthesis

Zhang,

Cao,

Liang

et al. 2024

ABBS

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease, with a global prevalence of 25%. Patients with NAFLD are more likely to suffer from advanced liver disease, cardiovascular disease, or type II diabetes. However, unfortunately, there is still a shortage of FDA-approved therapeutic agents for NAFLD. Lian-Mei-Yin (LMY) is a traditional Chinese medicine formula used for decades to treat liver disorders. It has recently been applied to type II diabetes which is closely related to insulin resistance. Given that NAFLD is another disease involved in insulin resistance, we hypothesize that LMY might be a promising formula for NAFLD therapy. Herein, we verify that the LMY formula effectively reduces hepatic steatosis in diet-induced zebrafish and NAFLD model mice in a time-and dose-dependent manner. Mechanistically, LMY suppresses Yap1-mediated Foxm1 activation, which is crucial for the occurrence and development of NAFLD. Consequently, lipogenesis is ameliorated by LMY administration. In summary, the LMY formula alleviates diet-induced NAFLD in zebrafish and mice by inhibiting Yap1/Foxm1 signaling-mediated NAFLD pathology.

show abstract

Section: Discussionmentioning

confidence: 99%

Lian-Mei-Yin formula alleviates diet-induced hepatic steatosis by suppressing Yap1/FOXM1 pathway-dependent lipid synthesis

Zhang,

Cao,

Liang

et al. 2024

ABBS

View full text Add to dashboard Cite

show abstract

“…(Asteraceae), and Gynostemma pentaphyllum (Thunb.) Makino (Cucurbitaceae), has been reported to be effective against MAFLD (Yu et al, 2021). Additionally, studies have shown that JZG can promote the maturation of intestinal mucosal DCs and induce the differentiation of immature CD4 + T cells into Th1 cells (Yu et al, 2021).…”

Section: Target Dendritic Cellsmentioning

confidence: 99%

“…Makino (Cucurbitaceae), has been reported to be effective against MAFLD (Yu et al, 2021). Additionally, studies have shown that JZG can promote the maturation of intestinal mucosal DCs and induce the differentiation of immature CD4 + T cells into Th1 cells (Yu et al, 2021). It can also reduce damage to the intestinal mucosal immune barrier and decrease liver fat in MASH rats, resulting in significant improvements in liver function and liver tissue pathology (Yu et al, 2021).…”

Section: Target Dendritic Cellsmentioning

confidence: 99%

Traditional Chinese medicines and natural products targeting immune cells in the treatment of metabolic-related fatty liver disease

Ouyang

Zhu

2023

Front. Pharmacol.

View full text Add to dashboard Cite

MAFLD stands for metabolic-related fatty liver disease, which is a prevalent liver disease affecting one-third of adults worldwide, and is strongly associated with obesity, hyperlipidemia, and type 2 diabetes. It encompasses a broad spectrum of conditions ranging from simple liver fat accumulation to advanced stages like chronic inflammation, tissue damage, fibrosis, cirrhosis, and even hepatocellular carcinoma. With limited approved drugs for MAFLD, identifying promising drug targets and developing effective treatment strategies is essential. The liver plays a critical role in regulating human immunity, and enriching innate and adaptive immune cells in the liver can significantly improve the pathological state of MAFLD. In the modern era of drug discovery, there is increasing evidence that traditional Chinese medicine prescriptions, natural products and herb components can effectively treat MAFLD. Our study aims to review the current evidence supporting the potential benefits of such treatments, specifically targeting immune cells that are responsible for the pathogenesis of MAFLD. By providing new insights into the development of traditional drugs for the treatment of MAFLD, our findings may pave the way for more effective and targeted therapeutic approaches.

show abstract

“…Altered lifestyles such as exercise and dietary restriction are commonly recommended treatments for MAFLD [52]. The bioactive components of the diet can have a positive impact on MAFLD by modulating the TLR4 Signaling Pathways in MAFLD Jiang Zhi granules DSS/NASH rats Inhibits the TLR4/MyD88 signaling pathway [100] TLR4, Toll-like receptor 4; HFD, high-fat diet; MAFLD, metabolic-associated fatty liver disease; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; MCD, choline-deficient diet; HFHC, high-fat and high-carbohydrate drinking diet; BPA, low-dose bisphenol A; HFGD, high-fat diet plus fructose/glucose drinking-water diet; DSS, dextran sulfate sodium.…”

Section: Altered Lifestylesmentioning

confidence: 99%

“…Certain traditional Chinese medicines, such as Chinese herbs, Chinese herbal formulations, and Chinese patent medicines, have shown effectiveness in reducing hepatic steatosis and inflammation in MAFLD (shown in Table 1) [73‒100].…”

Section: Therapeutic Strategies For Mafld Targeting Tlr4 Signaling Pa...mentioning

confidence: 99%

Mechanisms and Therapeutic Strategies for MAFLD Targeting TLR4 Signaling Pathways

Ren,

Bai,

et al. 2023

J Innate Immun

View full text Add to dashboard Cite

Background: Metabolic-associated fatty liver disease (MAFLD) is one of the most common chronic liver diseases. The underlying pathophysiological mechanisms are intricate and involve various factors. Unfortunately, there is currently a lack of available effective treatment options. Toll-like receptors (TLRs) are a group of pattern-recognition receptors that are responsible for activating the innate immune system. Research has demonstrated that TLR4 plays a pivotal role in the progression of MAFLD by facilitating the pathophysiological mechanisms. Summary: Lipid peroxidation, pro-inflammatory, insulin resistance (IR), and dysbiosis of intestinal microbiota are considered as the pathogenic mechanisms of MAFLD. This review summarizes the impact of TLR4 signaling pathways on the progression of MAFLD, specifically in relation to lipid metabolic disorders, IR, oxidative stress, and gut microbiota disorders. Additionally, we emphasize the potential therapeutic approaches for MAFLD that target TLR4 signaling pathways, including the use of plant extracts, traditional Chinese medicines, probiotics, pharmaceuticals such as PPAR antagonists and FXR agonists, and lifestyle modifications such as dietary changes and exercise also considered. Furthermore, TLR4 signaling pathways have also been linked to the lean MAFLD. Key Messages: TLR4 plays a crucial role in MAFLD by triggering insulin resistance, buildup of lipids, imbalance in gut microbiota, oxidative stress, and initiation of immune responses. The mitigation of MAFLD can be accomplished by suppressing the TLR4 signaling pathway. In the future, it could potentially emerge as a therapeutic target for the condition.

show abstract

Jiang Zhi Granule protects immunological barrier of intestinal mucosa in rats with non-alcoholic steatohepatitis

Cited by 5 publications

References 50 publications

Lian-Mei-Yin formula alleviates diet-induced hepatic steatosis by suppressing Yap1/FOXM1 pathway-dependent lipid synthesis

Lian-Mei-Yin formula alleviates diet-induced hepatic steatosis by suppressing Yap1/FOXM1 pathway-dependent lipid synthesis

Traditional Chinese medicines and natural products targeting immune cells in the treatment of metabolic-related fatty liver disease

Mechanisms and Therapeutic Strategies for MAFLD Targeting TLR4 Signaling Pathways

Contact Info

Product

Resources

About